An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
| Autor: | Irina Koroleva, Joan Carles, Fadi El Karak, Denise Bury, Hana Korunkova, Joseph Makdessi, Marwan Ghosn, Simon Hitier, Jana Katolicka, Antoaneta Tomova, Angelika Pichler, Ayse Özatilgan, Gisoo Barnes |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pichler A] Department of Hematology and Oncology, Landeskrankenhaus Hochsteiermark, Leoben, Austria. [Korunkova H] Department of Oncology and Radiotherapy, University Hospital, Plzen, Czech Republic. [Tomova A] Department of Oncology, Complex Oncology Center, Plovdiv, Bulgaria. [Ghosn M, El Karak F] Department of Hematology and Oncology, Hotel Dieu de France University Hospital, Saint Joseph University, Beirut, Lebanon, Vall d'Hebron Barcelona Hospital Campus, Hospital Universitari Vall d'Hebron |
| Rok vydání: | 2018 |
| Předmět: |
Male
Neutrophils Urological Oncology #PCSM Phases of clinical research Docetaxel Prostate cancer 0302 clinical medicine Quality of life Antineoplastic Combined Chemotherapy Protocols 030212 general & internal medicine Aged 80 and over health‐related quality of life metastatic castration‐resistant prostate cancer Middle Aged mCRPC real‐world Diagnosis::Prognosis::Treatment Outcome::Progression-Free Survival [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Progression-Free Survival Survival Rate Prostatic Neoplasms Castration-Resistant #ProstateCancer Cabazitaxel 030220 oncology & carcinogenesis Taxoids Cohort study medicine.drug Adult medicine.medical_specialty diagnóstico::pronóstico::resultado del tratamiento::supervivencia libre de progresión [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Urology HRQoL terapéutica::farmacoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Therapeutics::Drug Therapy [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] 03 medical and health sciences Metàstasi Internal medicine medicine Humans Adverse effect Aged business.industry cabazitaxel Pròstata - Càncer - Tractament medicine.disease Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms Male::Prostatic Neoplasms::Prostatic Neoplasms Castration-Resistant [DISEASES] Comorbidity neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración [ENFERMEDADES] Quality of Life business Follow-Up Studies |
| Zdroj: | Scientia Recercat: Dipósit de la Recerca de Catalunya Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) Recercat. Dipósit de la Recerca de Catalunya instname Bju International |
| ISSN: | 1464-4096 |
| DOI: | 10.1111/bju.14509 |
| Popis: | Càncer de pròstata resistent a la castració metastàsica; Cabazitaxel; Qualitat de vida relacionada amb la salut Cáncer de próstata metastásico resistente a la castración; Cabazitaxel; Calidad de vida relacionada con la salud Metastatic castration-resistant prostate cancer; Cabazitaxel; Health-related quality of life Objectives To obtain routine clinical practice data on cabazitaxel usage patterns for patients with metastatic castration‐resistant prostate cancer (mCRPC) and to describe physician‐assessed cabazitaxel effectiveness, health‐related quality of life (HRQoL) and safety. Patients and Methods CAPRISTANA was an international, observational cohort study examining cabazitaxel use for the treatment of patients with mCRPC. Effectiveness was assessed by overall survival (OS), progression‐free survival (PFS), time to treatment failure (TTF) and disease control rate. HRQoL was assessed using the Functional Assessment of Cancer Therapy‐Prostate questionnaire (FACT‐P) and the three‐level European Quality of Life questionnaire (EQ‐5D‐3L). Safety was assessed by adverse event (AE) reporting. Results A total of 189 patients were treated across 54 centres between April 2012 and June 2016. At baseline, 58.7% had ≥1 comorbidity, 93.7% had an Eastern Cooperative Oncology Group performance status ≤1, and 60.1% had a Gleason score at diagnosis of ≥8. Patients received a median of 6 cabazitaxel cycles; 84.7% received cabazitaxel as second‐line therapy. The median OS, PFS and TTF were 13.2, 5.6 and 4.4 months, respectively. Cabazitaxel led to disease control in 52.9% of patients. HRQoL was maintained (40.3%) or improved (32.2%) in 72.5% of patients based on total FACT‐P scores. Interestingly, 53.6% of patients reported pain improvement and a further 21.2% maintained pain control based on FACT‐P prostate cancer‐specific pain scores. The most common treatment‐related grade ≥3 AEs were neutropenia (7.9%) and anaemia (2.1%). Conclusion Patients in CAPRISTANA treated with cabazitaxel had similar disease outcomes and safety profiles compared with large phase III clinical trials. Most patients had maintained or improved HRQoL scores; >70% of patients had maintained or improved pain control. Research and analysis was supported by Sanofi. The authors were responsible for all content and editorial decisions, and received no honoraria for development of this manuscript. Editorial support was provided by Amber Wood and Anna Longjaloux of MediTech Media, funded by Sanofi. The authors would also like to thank Teri Michelini of Sanofi for support in preparing this manuscript. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|